University of California

Lawrence Livermore National Security, LLC

The United States Government As Represented by the Department of Veterans Affairs

Maike Zimmermann

Paul Henderson

Chong-Xian Pan

Ralph William De Vere White

Bruce D Hammock

George D Cimino

Sung Hee Hwang

Kenneth W Turteltaub

Hongyong Zhang

Fuli Wang

Ai-Hong Ma

The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.

Methods for cytotoxic chemotherapy-based predictive assays

Provided are methods and compositions for prolonging survival and/or reducing or inhibiting tumor growth in a cancer subject receiving a regimen of one or more chemotherapeutic agents, an inhibitor of soluble epoxide hydrolase (sEHi) and a non-steroidal anti-inflammatory drug (NSAID) that inhibits one or more enzymes selected from the group consisting of cyclo-oxygenase ('COX')-1, COX-2, and 5-lipoxygenase ('5-LOX'). The methods and compositions decrease toxicity and/or adverse side effects in subjects receiving a regimen of one or more chemotherapeutic agents.

Methods of improving cancer chemotherapy

Growing community of inventors

Sacramento, CA, United States of America

Maike Zimmermann